問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Linkou Chang Gung Medical Foundation

List

2449Cases

2019-08-22 - 2021-08-25

Phase I

A PHASE 1, OPEN-LABEL, SINGLE-DOSE STUDY TO ASSESS THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF CEFTAZIDIME-AVIBACTAM (CAZ-AVI) IN CHILDREN FROM 3 MONTHS TO LESS THAN 18 YEARS OF AGE WHO ARE HOSPITALIZED AND RECEIVING SYSTEMIC ANTIBIOTIC THERAPY FOR SUSPECTED OR CONFIRMED NOSOCOMIAL PNEUMONIA, INCLUDING VENTILATOR-ASSOCIATED PNEUMONIA

  • Condition/Disease

    Hospitalized Children With Suspected or Confirmed Nosocomial Pneumonia

  • Test Drug

    ceftazidime-avibactam

Participate Sites
7Sites

Recruiting7Sites

2019-05-01 - 2021-08-26

Phase II/III

A PHASE 2B/3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF-06651600 IN ADULT AND ADOLESCENT ALOPECIA AREATA (AA) SUBJECTS WITH 50% OR GREATER SCALP HAIR LOSS

  • Condition/Disease

    Alopecia Areata (AA)

  • Test Drug

    PF-06651600

Participate Sites
6Sites

Recruiting6Sites

2014-04-30 - 2017-04-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2016-04-16 - 2018-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated2Sites

張廷彰
Linkou Chang Gung Medical Foundation

未分科

2016-01-01 - 2021-05-31

Phase I/II

A Phase I/II Study of CX-4945 in Combination with Gemcitabine plus Cisplatin in the Frontline Treatment of Patients with Cholangiocarcinoma

  • Condition/Disease

    Cholangiocarcinoma

  • Test Drug

    CX-4945

Participate Sites
7Sites

Recruiting6Sites

白禮源
China Medical University Hospital-Taipei

未分科

陳明晃
Taipei Veterans General Hospital

Division of Hematology & Oncology

2016-07-01 - 2019-12-24

Phase III

A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH AND/OR FOLLOWING CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED EPITHELIAL OVARIAN CANCER

  • Condition/Disease

    Epithelial Ovarian Cancer

  • Test Drug

    MSB0010718C 20mg/ml Solution for Infusion

Participate Sites
7Sites

Terminated7Sites

王鵬惠
Taipei Veterans General Hospital

Division of Obstetrics & Gynecology

2016-01-04 - 2019-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2015-05-01 - 2019-12-31

Phase III

A Randomized, Double-Blind, Multi-Center, Parallel Group Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 on COPD Exacerbations over a 52-Week Treatment Period in Subjects With Moderate to Very Severe COPD

  • Condition/Disease

    chronic obstructive pulmonary disease (COPD)

  • Test Drug

    PT010, PT003, PT009

Participate Sites
9Sites

Terminated9Sites

2015-09-01 - 2016-12-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

邱政洵
Linkou Chang Gung Medical Foundation

Division of Pediatrics

2017-07-01 - 2020-08-22

Phase II

A Randomized, Multicenter, Adaptive Phase 3 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy (WIZARD 201G)

  • Condition/Disease

    Recurrent or Progressive Glioblastoma following Initial Therapy

  • Test Drug

    DSP-7888

Participate Sites
3Sites

Recruiting3Sites

魏國珍
Linkou Chang Gung Medical Foundation

Division of Orthopedics

1 211 212 213 214 215 245
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB